NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Objectives The LRRK2 p.Gly2019Ser pathogenic variant has reduced penetrance and presents a wide range of age at onset (AAO) in patients with Parkinson’s disease (PD). We aim to elucidate differences in the cumulative incidence of LRRK2 p.Gly2019Ser - related PD ( LRRK2 -PD) between ancestries and countries. Methods We included N=922 unrelated LRRK2 p.Gly2019Ser variant carriers (affected: N=762, unaffected: N=160) from the Global Parkinson’s Genetics Program (GP2) in addition to cohorts recruited from the Israeli Ashkenazi Jewish and Tunisian Arab-Berber population. The p.Gly2019Ser variant was present in five ancestries: Ashkenazi Jewish (N=534), North African (N=223), European (N=132), Middle Eastern (N=19) and Latino and Indigenous people of the Americas (N=14). In addition to ancestry derived from the genetic data, we assessed the country of origin in our analysis. The Cox proportional-hazards model and Kaplan-Meier analysis were applied to examine differences in cumulative incidence. All analyses were adjusted for biological sex, and the outcome variable was AAO, including affected and unaffected variant carriers with right censoring for affection status, and all analysis were exploratory. Results The median AAO of LRRK2 -PD was five years younger in the North African (HR=1.48, 95% CI: 1.18-1.86, p=7.0×10 −4 ) compared to the European ancestry group. In contrast, the median AAO was five years older in the Ashkenazi Jewish (HR=0.61, 95% CI: 0.50-0.75, p=4.0×10 −6 ) compared to the European ancestry group. Additionally, patients from Israel (HR=1.59, 95% CI: 1.30-1.39, p=4.0×10 −6 ) and Tunisia (HR=2.57, 95% CI: 2.16-3.06, pDiscussion Our results provide evidence that a person’s genetic ancestry and country of origin are associated with the AAO of LRRK2 -PD. This highlights the potential impact of both genetic and environmental factors on LRRK2 -PD AAO.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.